Democratic Party leaders and their donors bear responsibility for the increasingly widespread view of trans rights as ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...

Reporting in recent days has indicated that the two top contenders to lead the Treasury Department in the second Trump administration are billionaires: hedge fund manager and Trump megadonor Scott ...

Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca. Just after market closed today, we ...

Research by a team of academics into the effects of long Covid has been described as a ‘model for the future of health ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter ... Updated ago Technologycategory Pinterest ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City, ...